Valneva's Stock Rises 3.3% in Session Despite Lowered 2025 Targets

Annual Performance and Recent Challenges

On a broader horizon, the stock shows a weekly performance of 4.5% and a three-month increase of 2.17%. Even more notably, the stock has gained 80.54% over the year, significantly outperforming the Paris index, which only rose by 14.5% over the same period. However, this strong annual momentum contrasts with recent turbulence in the case. On Monday, November 10, Valneva announced a downward revision of its financial forecasts for 2025, following the FDA's suspension last August of its Ixchiq vaccine license for chikungunya. The company now expects sales to be between 155 and 170 million euros, compared to 170 to 180 million previously.

Technical Perspective and Market Position

From a technical standpoint, the stock is in a mixed configuration. The current price of 4.044 euros is below the 50-day moving average of 4.20 euros, indicating persistent selling pressure in the medium term. However, the stock remains solidly above its 200-day moving average set at 3.42 euros, confirming a constructive long-term underlying trend. This gap of more than 62 cents with the MM200 reflects the strong appreciation of the stock since the beginning of the year, despite recent regulatory difficulties. The RSI (Relative Strength Index) shows a reading of 41, placing the stock in a slightly bearish neutrality zone, close but outside the oversold territory (generally under 30). This value suggests that selling pressure has eased without yet shifting into a distinctly bullish dynamic. This indicator hints at technical room for further rebound if investor sentiment were to improve, particularly with progress on the American regulatory file or positive news on the company's pipeline.